The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey
Open accessAbstract
Glycosylation is among the most important post-translational modifications for proteins and is of intrinsic complex character compared with DNAs and naked proteins. Indeed, over 50%–70% of proteins in circulation are glycosylated, and the “sweet attachments” have versatile structural and functional implications. Both the configuration and composition of the attached glycans affect the biological activities of consensus proteins significantly. Glycosylation is generated by complex biosynthetic pathways comprising hundreds of glycosyltransferases, glycosidases, transcriptional factors, transporters and the protein backbone. In addition, lack of direct genetic templates and glyco-specific antibodies such as those commonly used in DNA amplification and protein capture makes research on glycans and glycoproteins even more difficult, thus resulting in sparse knowledge on the pathophysiological implications of glycosylation. Fortunately, cutting-edge technologies have afforded new opportunities and approaches for investigating cancer-related glycosylation. Thus, glycans as well as aberrantly glycosylated protein-based cancer biomarkers have been increasingly recognized. This mini-review highlights the most recent developments in glyco-biomarker studies in an effort to discover clinically relevant cancer biomarkers using advanced analytical methodologies such as mass spectrometry, high-performance liquid chromatographic/ultra-performance liquid chromatography, capillary electrophoresis, and lectin-based technologies. Recent clinical-centered glycobiological studies focused on determining the regulatory mechanisms and the relation with diagnostics, prognostics and even therapeutics are also summarized. These studies indicate that glycomics is a treasure waiting to be mined where the growth of cancer-related glycomics and glycoproteomics is the next great challenge after genomics and proteomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sialic acids sweeten a tumor's life
Büll, C., Stoel, M. A., den Brok, M. H., & Adema, G. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0728 · Cited by 496
Taniguchi (2015) · doi:10.1016/bs.acr.2014.11.001 · Cited by 381 · cited 1×
“Sialyltransferases (STs) [111], fucosyltransferases (FUTs) [112, 113] and N-acetylglucosaminyltransferases (GnTs) [114, 115] represent a part of glycosyltransferases responsible for the formation of a manifold of glyco-phenotypes, and are currently the most studied molecules in glycobiology [116, 117].”
O'Brien, D. P., Sandanayake, N. S., Jenkinson, C., Gentry-Maharaj, A., Apostolidou, S., Fourkala, E.-O., Camuzeaux, S., Blyuss, O., Gunu, R., Dawnay, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0365 · Cited by 200
Wannhoff, A., Hov, J. R., Folseraas, T., Rupp, C., Friedrich, K., Anmarkrud, J. A., Weiss, K. H., Sauer, P., Schirmacher, P., Boberg, K. M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.005 · Cited by 94
Training the next generation of biomedical investigators in glycosciences
Agre, P., Bertozzi, C., Bissell, M., Campbell, K. P., Cummings, R. D., Desai, U. R., Estes, M., Flotte, T., Fogleman, G., Gage, F., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85905 · Cited by 34
Cited by
Fluorescent probes for the detection of disease-associated biomarkers
Dou, W.-T., Han, H.-H., Sedgwick, A. C., Zhu, G.-B., Zang, Y., Yang, X.-R., Yoon, J., James, T. D., Li, J., & He, X.-P. (2022) · Science Bulletin · doi:10.1016/j.scib.2022.01.014 · Cited by 266
Glycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications
Qusairy, Z., & Rada, M. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05303-1 · Cited by 16
Unraveling the glycosylated immunopeptidome with HLA-Glyco
Bedran, G., Polasky, D. A., Hsiao, Y., Yu, F., da Veiga Leprevost, F., Alfaro, J. A., Cieslik, M., & Nesvizhskii, A. I. (2023) · Nature Communications · doi:10.1038/s41467-023-39270-2 · Cited by 15
Yingli, H., Ping, Y., Jun, Y., & Xingwang, Z. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167853 · Cited by 7
Metadata
- Authors
- Wang, M., Zhu, J., Lubman, D. M., & Gao, C.
- Venue
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Publisher
- Walter de Gruyter GmbH
- Published
- 2018-08-23
- Volume
- 57
- Issue
- 4
- Pages
- 407-416
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W2888640582
- Cited by
- 178
- References
- 5
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey. https://app.cochat.ai/papers/10.1515/cclm-2018-0379
- The paper
- Wang, M., Zhu, J., Lubman, D. M., & Gao, C. (2019). Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2018-0379
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.